Anders Holm

Anders Holm has a diverse work experience spanning over 20 years. Anders began their career at Amersham Health as a Researcher in 2001 before moving on to Atlantis Medisinske Høyskole as a Lecturer in 2005. In 2004, Holm worked as a Post Doctoral Scientist at the Institute of Immunology, Rikshospitalet University Hospital, where they contributed to building the Proteomics Core Facility and conducted research on autoimmune diseases.

In 2007, Holm joined the University of Oslo/Birkeland Innovation as a Project Manager, where they gained experience in project management. From 2008 to 2010, they worked as a Scientist at the Institute of Immunology, Oslo University Hospital - Rikshospitalet, focusing on developing and utilizing bead-based antibody arrays for cancer cell characterization.

Holm then transitioned to a Post Doc position at the Norwegian PSC Research Center, Clinic for Specialized Medicine and Surgery, Oslo University Hospital from 2011 to 2013. During this time, they furthered their research expertise.

In 2013, Holm joined Inven2 as a Technology Strategy Manager, where they were responsible for commercialization of life science inventions, with a particular focus on immuno-oncology and immunology. Anders also served as the project leader for the Zelluna Immunotherapy case.

From 2017, Holm became involved with Zelluna Immunotherapy, initially as Director of Operations. Anders then moved up to the role of Chief Operating Officer and later took on the additional responsibilities of Head of Business Development.

Anders Holm pursued their educational journey in the field of Analytical Chemistry. Anders began their academic path in 1999 at the University of Oslo (UiO), where they earned a Master of Science (M.Sc) degree in Analytical Chemistry in 2001. Showing dedication and passion for their field, Anders continued their studies at UiO and completed their doctoral degree in Analytical Chemistry in 2004, obtaining a Ph.D. from the University of Oslo.